Related Experiment Video
Updated: Aug 15, 2026

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
Current concepts: large granular lymphocyte leukemia
1H. Lee Moffitt Cancer Center and the Veterans' Administration Hospital, Department of Internal Medicine, University of South Florida, Tampa, USA.
Insights
Large granular lymphocyte (LGL) leukemia, a clonal disorder affecting T-cells or NK-cells, often presents in elderly individuals with symptoms like neutropenia and anemia. Methotrexate can induce remission, but drug resistance is a challenge.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Large granular lymphocyte (LGL) disorders are clonal conditions originating from either T-cell or NK-cell lineages.
- CD3+ T-cell LGL leukemia is the predominant form, typically affecting elderly patients.
- Clinical manifestations include neutropenia, anemia, and rheumatoid arthritis, with T-cell LGL leukemia often presenting with a CD3+, alphabeta+, CD8+, CD57+ phenotype.
Purpose of the Study:
- To elucidate the pathogenesis and clinical features of T-cell and NK-cell LGL leukemia.
- To investigate the role of cytokines and apoptotic pathway defects in LGL leukemia.
- To explore potential therapeutic strategies and resistance mechanisms in LGL leukemia.
Main Methods:
- Analysis of LGL phenotypes (e.g., CD3, CD8, CD57).
- Detection of clonality via T-cell receptor gene rearrangement.
- Assessment of cytokine expression (IL12, IL15) and apoptotic pathway components (Fas, Fas-Ligand).
- Evaluation of serologic reactivity (HTLV-I env p21e homology) and drug resistance markers (PgP+/LRP+).
Main Results:
- T-LGL leukemia, the most common type, affects elderly individuals with symptoms like neutropenia and anemia.
- NK-cell LGL disorders include aggressive NK LGL leukemia and chronic lymphocytosis.
- Leukemic LGL cells exhibit resistance to Fas-induced apoptosis and constitutively express Fas/Fas-Ligand; soluble Fas-Ligand may cause neutropenia.
- Reactivity to HTLV-I env p21e suggests a role for homologous proteins in pathogenesis.
- Leukemic LGLs express multidrug resistance proteins (PgP+/LRP+), contributing to chemoresistance.
Conclusions:
- LGL leukemia pathogenesis involves dysregulated apoptosis, potentially linked to cytokines like IL12/IL15 and defective Fas signaling.
- Low-dose methotrexate can achieve clinical and molecular remission.
- LGL leukemia serves as a model for understanding how dysregulated apoptosis contributes to malignancy and autoimmune diseases.
- Multidrug resistance phenotype contributes to treatment challenges in aggressive cases.
Abstract:
Clonal diseases of large granular lymphocyte (LGL) disorders can arise from a CD3+ T-cell lineage or from a CD3- NK-cell lineage. CD3+ LGL leukemia is the most frequent form of LGL leukemia. T-LGL leukemia usually affects elderly people. Approximately 60% of patients are symptomatic; recurrent infections secondary to chonic neutropenia, anemia, and rheumatoid arthrititis are the main clinical manifestations. The most common phenotype is CD3+, alphabeta+, CD8+, CD57+. Clonality is detected by clonal rearrangement of the T-cell receptor gene. NK-cell LGL proliferative disorders include NK LGL leukemia which is a very aggressive disease and NK chronic lymphocytosis. Serologic findings show frequent reactivity to the BA21 epitope of HTLV-I env p21e, suggesting that a cellular or retroviral protein with homology to BA21 may be important in pathogenesis of these diseases. Clonal expansion may be facilitated by IL12 and IL15 cytokines expressed by leukemic LGL, and also by a defective Fas (CD95) apoptotic pathway. Leukemic LGL constitutively express Fas and Fas-Ligand but they are resistant to Fas-induced apotosis. Neutropenia could be due to soluble Fas-Ligand which is highly secreted in the patient's sera. Clinical and molecular remission can be obtained with oral low-dose methotrexate. Leukemic LGL express a multi-drug resistance phenotype (PgP+/LRP+) that could partly explain the chemoresistance observed in aggressive cases. It is suggested that LGL leukemia can serve as a useful model of dysregulated apoptosis as an underlying mechanism for both malignancy and autoimmune disease.
More Related Videos
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Related Concept Videos
Differentiation of Common Myeloid Progenitor Cells
Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Lymphoid Cells and Tissues
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
Primary Lymphoid Organs
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Secondary Lymphoid Organs
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
Cells of the Adaptive Immune Response